Warfarissimo
Referinte bibliografice

Simulati
Exemple
Utilizare
Metoda
Participati
Referinte
Publicatii
EN
Diacritice

  1. Jack Ansell, Jack Hirsh, James Dalen, Henry Bussey, David Anderson, Leon Poller, Alan Jacobson, Daniel Deykin, and David Matchar. Managing oral anticoagulant therapy. Chest, 119:22S-38S, 2001.
  2. I Petitpas, A A Bhattacharya, S Twine, M East, and S Curry. Crystal structure analysis of warfarin binding to human serum albumin. The Journal of Biological Chemistry, 276(25):22804-22809, 2001.
  3. Louis E Penrod, Joanne B Allen, and Leonard R Cabacungan. Warfarin resistance and enteral feedings: 2 case reports and a supporting in vitro study. Arch Phys Med Rehabil, 82:1270-1273, sep 2001. P9/2003.
  4. Joel G Hardmann and E Limbird, Lee, editors. The Pharmacological Basis of Therapeutics. McGrawHill, 10 edition, 2002.
  5. H K Thijssen, M J Drittij, L M T Vervoort, and J C de Vries-Hanje. Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3. Clin Pharmacol Ther, 70:292-298, 2001.
  6. Craig R Lee, Joyce A Goldstein, and John A Pieper. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics, 12:251-263, 2002.
  7. Dolors Tassies, Carolina Freire, Santiago Pijoan, Josefina Maragall, Joan Montegudo, Antoni Ordinas, and Joan Carles Reverter. Phamacogenetics of acenocoumarol: cytochrome p450-cyp2c9 polymorphisms influence dose requirements and stability of anticoagulation. Haematologica, 87:1185-1191, 2002.
  8. H K Thijssen, J P Flinois, and P H Beaune. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metabolism and Disposition, 28(1):1284-1290, 2000.
  9. G P Aithal, C P Day, P J L Kesteven, and A K Daly. Association of polymorphisms in the cytochrome p450-cyp2c9 with warfarin dose requirement and risk of bleeding complications. Lancet, 353:717-719, 1999.
  10. J Taube, D Halsall, and T Baglin. Influence of cytochrome p-450 cyp2c9 polymorfisms on warfarin sensitivity and risk of overcoagulation in patients on long-term treatment. Blood, 96:1816-1819, 2000.
  11. M Margaglione, D Colaizzo, G D Andrea, V Brancaccio, A Ciampa, and E Grandone. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost, 84:775-778, 2000.
  12. D Cain, S M Hutson, and Reidar Wallin. Assembly of the warfarin-sensitive vitamin K 2,3-epoxide reductase enzyme complex in the endoplasmic reticulum membrane. The Journal of Biological Chemistry, 272(46):29068-29075, 1997.
  13. M J Fasco and L M Principe. R- and S-warfarin inhibition of vitamin K and vitamin K 2,3-epoxide reductase activities in the rat. J Biol Chem, 257:4894-4901, 1982.
  14. Saulius Butenas, Cornelis van't Veer, and Kenneth G Mann. "normal" thrombin generation. Blood, 94(7):2169-2178, oct 1999.
  15. D'Angelo Armando, Patrizia Della Valle, Luciano Crippa, Annalisa Fattorini, Elisabeta Pattarini, and Silvana Vigano D'Angelo. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anitcoagulant treatment. Haematologica, 87:1074-1080, 2002.
  16. C Verstuyft, S Morin, A Robert, M A Loriot, P Beaune, P Jaillon, and L Becquemont. Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers. Pharmacogenetics, 11:735-737, 2001.
  17. C S Landefeld, M W Rosenblatt, and L Goldman. Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remedial lesions. Am J Med, 87:153-159, 1989.
  18. M J Gitter, T M Jaeger, and T M Petterson. Bleeding and thromboembolism during anticoagulant therapy: a population based study in Rochester, minnesota. Mayo Clin Proc, 70:725-733, 1995.
  19. R J Beyth, L M Quinn, and S Landefeld. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med, 105:91-99, 1998.
  20. J C Fosfar. Prediction of hemorrhage during long-term oral coumarin anticoagulation by excessive prothrombin ratio. Am Heart J, 103:445-446, 1982.
  21. S D Fihn, M McDonell, and D Martin. Risk factors for complications of chronic anticoagulation: a multicenter study. Ann Intern Med, 118:511-520, 1993.
  22. F J M van der Meer, F R Rosendaal, and J P Vandenbroucke. Bleeding complications in oral anticoagulant therapy: and analysis of risk factors. Arch Intern Med, 153:1557-1562, 1993.
  23. S C Cannegieter, F R Rosendaal, and A R Wintzen. The optimal intensity of oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. New Engl J Med, 333:5-10, 1995.
  24. G Palaretti, N Leali, and S Coccheri. Bleeding and complications of oral anticoagulant treatment: an inception-cohort, prospective colaborative study (ISCOAT). Lancet, 348:423-428, 1996.
  25. T Holm, J F Lassen, and S E Husted. Identification and surveillance of patient on oral anticoagulant therapy in a large geographic area_use of laboratory information systems. Thromb Haemost, 82(suppl):858-859, 1999.
  26. R J Beyth and C S Landefeld. Prevention of major bleeding in older patients treated with warfarin: results of a randomised trial. J Gen Intern Med, 12:66, 1997.
  27. P T Sawicki. A structured teaching and self-management program for patient receiving oral anticoagulation: a randomized controlled trial: working group for the study of patient self-management of oral anticoagulation. JAMA, 281:145-150, 1999.
  28. B S P Hellemons, M Langenberg, and J Lodder. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomized controlled trial comparing two intensities of coumarin with aspirin. BMJ, 319:958-964, 1999.
  29. P Petersen, G Boysan, and J Godtfredsen. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the copenhagen AFASAK study. Lancet 341:175-179, 1989.
  30. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med, 323:1505-1511, 1990.
  31. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-ntensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomized clinical trial. Lancet, 348:633-638, 1996.
  32. M D Ezekowitz, S L Bridgers, and K E Jmes. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med, 327:1406-1412, 1992.
  33. S J Connolly, A Laupacis, and M Cent. Canadian atrial fibrillation anticoagulation (cafa) study. J Am Coll Cardiol, 18:349-355, 1991.
  34. A L Gullov, B G Koefoed, and P Petersen. Bleeding during warfarin and aspirin therapy in patients treated with atrial fibrillation: the AFASAK 2 study. Arch Intern Med, 159:1322-1328, 1999.
  35. European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet, 342:1255-1262, 1993.

Numele dvs (optional):
Adresa dvs de e-mail* (optional):
Subiect:
Comentariu:

*Vom folosi adresa dvs doar pentru a va raspunde la mesaj.

(c) 2005-2008 A.D. Corlan